Longest Clinical Trial on Osteoporosis Finds Fosamax Safe and Effective

JULY 01, 2004

After 10 years of clinical trials, researchers have determined that the bisphosphonate Fosamax enables postmenopausal women to maintain or increase bone density with no poor effects. Even after use of the drug was stopped, some women continued to show improvement in bone density. Because osteoporosis is a chronic condition requiring long-term treatment, results of a 10-year study are very important, according to the study's director, Henry G. Bone, MD, of the St. John Hospital and Medical Center in Detroit, Mich.

Other experts, however, cautioned that more research is needed to determine how long patients need to take Fosamax and when they should begin taking the drug. They also noted that the study's measure of success was bone density rather than risk of bone fracture. While Fosamax is the most commonly used drug for osteoporosis, more research is needed on dosing and scheduling.


Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?

Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.